PubRank

Gerard Espinosa

Author PubWeight™ 76.94‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007 2.91
2 Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia 2012 2.08
3 [Antiphospholipid syndrome: analysis of 27 patients]. Med Clin (Barc) 2013 1.98
4 Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010 1.77
5 Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. Ann Emerg Med 2003 1.66
6 Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo? Trends Immunol 2008 1.64
7 Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006 1.53
8 Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) 2013 1.46
9 Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant 2012 1.45
10 [Basic cardiopulmonary resuscitation program for high school students (PROCES). Results from the pilot program]. Med Clin (Barc) 2005 1.42
11 Immunosuppression and Chagas disease: a management challenge. PLoS Negl Trop Dis 2013 1.12
12 Etiopathogenesis of Behcet's disease. Autoimmun Rev 2009 1.11
13 Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med 2007 1.11
14 Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum 2005 1.07
15 Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) 2012 1.05
16 A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis 2010 1.05
17 Effects of external and internal factors on emergency department overcrowding. Ann Emerg Med 2002 1.04
18 Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013 1.04
19 Factors influencing polyautoimmunity in systemic lupus erythematosus. Autoimmun Rev 2009 0.99
20 Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol 2007 0.99
21 Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol 2002 0.97
22 Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002 0.96
23 Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 2007 0.95
24 Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006 0.95
25 The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 2007 0.95
26 A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet 2013 0.94
27 Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. Semin Arthritis Rheum 2007 0.93
28 Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. Arthritis Res Ther 2013 0.93
29 Epidemiology and management of refractory lupus nephritis. Autoimmun Rev 2011 0.92
30 Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". Semin Thromb Hemost 2012 0.92
31 Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013 0.90
32 A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res Ther 2012 0.90
33 Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study. Ann Rheum Dis 2012 0.89
34 Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013 0.89
35 Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev 2011 0.89
36 Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol 2012 0.88
37 Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy. Isr Med Assoc J 2006 0.88
38 Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. Rheumatology (Oxford) 2011 0.88
39 Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy. Clin Lab Med 2013 0.87
40 Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol 2009 0.87
41 Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010 0.87
42 Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 2007 0.85
43 Current and future treatments for Behçet's uveitis: road to remission. Int Ophthalmol 2013 0.85
44 HLA and non-HLA genes in Behçet's disease: a multicentric study in the Spanish population. Arthritis Res Ther 2013 0.85
45 Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. Ann Rheum Dis 2011 0.85
46 Genotypes coding for low serum levels of mannose-binding lectin are underrepresented among individuals suffering from noninfectious systemic inflammatory response syndrome. Clin Vaccine Immunol 2009 0.84
47 Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev 2006 0.83
48 Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis 2012 0.83
49 Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. Arthritis Res Ther 2012 0.83
50 Registry of the Spanish network of Behçet's disease: a descriptive analysis of 496 patients. Clin Exp Rheumatol 2014 0.82
51 Val247Leu β2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis. Autoimmun Rev 2012 0.82
52 Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum 2008 0.82
53 Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet's disease. Hum Immunol 2012 0.81
54 Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg 2009 0.81
55 Venous thromboembolic disease in systemic autoimmune diseases: an association to keep in mind. Autoimmun Rev 2012 0.80
56 [Direct discharge from triage in emergency departments: assessment, risks and patient satisfaction]. Med Clin (Barc) 2006 0.80
57 Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken) 2012 0.79
58 Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 2012 0.79
59 Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore) 2014 0.79
60 [Role of biologic therapy in systemic autoimmune diseases]. Med Clin (Barc) 2007 0.79
61 High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature. Medicine (Baltimore) 2013 0.79
62 Connective tissue diseases: classification criteria for SLE: the latest-but not least-attempt. Nat Rev Rheumatol 2012 0.79
63 ADAMTS-13 in Critically Ill Patients With Septic Syndromes and Noninfectious Systemic Inflammatory Response Syndrome. Shock 2015 0.79
64 Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"--a tribute to the late Josep Font. Ann N Y Acad Sci 2007 0.79
65 Catastrophic APS in the context of other thrombotic microangiopathies. Curr Rheumatol Rep 2015 0.78
66 [Emergency department overcrowding: quantification of associated factors]. Med Clin (Barc) 2003 0.78
67 [Behçet disease]. Med Clin (Barc) 2006 0.78
68 Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. Clin Exp Rheumatol 2014 0.78
69 Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis. Eur J Ophthalmol 2012 0.77
70 Gastrointestinal-associated autoantibodies in different autoimmune diseases. Am J Clin Exp Immunol 2012 0.77
71 Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: a systematic review and meta-analysis. Autoimmun Rev 2012 0.77
72 Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thromb Haemost 2009 0.77
73 Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Int Ophthalmol 2010 0.77
74 Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS Registry". Autoimmun Rev 2013 0.77
75 Solid cancer, antiphospholipid antibodies, and venous thromboembolism. Autoimmun Rev 2010 0.77
76 Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol Res 2013 0.76
77 Catastrophic antiphospholipid syndrome: an orchestra with several musicians. Isr Med Assoc J 2014 0.76
78 Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies. J Reprod Immunol 2010 0.75
79 Auscultation of Velcro Crackles is Associated With Usual Interstitial Pneumonia. Medicine (Baltimore) 2016 0.75
80 Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. Arthritis Rheum 2002 0.75
81 The anti-phospholipid syndrome: 30 years in the forefront (1983-2013). Rheumatology (Oxford) 2013 0.75
82 Lupus around the world. Acta Reumatol Port 2007 0.75
83 Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies. Expert Opin Ther Targets 2010 0.75
84 Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome? Clin Exp Rheumatol 2013 0.75
85 Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev 2006 0.75
86 No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis. Clin Exp Rheumatol 2011 0.75
87 Repeated Renal Biopsy - A Predictive Tool to Assess the Probability of Renal Flare in Lupus Nephritis. Am J Nephrol 2016 0.75
88 Catastrophic antiphospholipid syndrome - 20 years later. Curr Rheumatol Rev 2013 0.75
89 Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis. Am J Reprod Immunol 2009 0.75
90 Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. Ann Rheum Dis 2011 0.75
91 Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. Autoimmun Rev 2006 0.75
92 Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: A systematic literature review. Medicine (Baltimore) 2017 0.75
93 [Biological therapies in systemic lupus erythematosus]. Rev Med Chil 2010 0.75
94 TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA. Retina 2017 0.75